2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

Genest, Jacques; McPherson, Ruth; Fröhlich, Jiří; Anderson, Todd J.; Campbell, Norm R.C.; Carpentier, André C.; Couture, Patrick; Dufour, Robert; Fodor, George; Francis, Gordon A.; Grover, Steven A.; Gupta, Milan; Hegele, Robert A.; Lau, David C.W.; Leiter, Lawrence A.; Lewis, Gary F.; Lonn, Eva; Mancini, G.B. John; Ng, Dominic S.; Pearson, Glen J.; Sniderman, Allan D.; Stone, James A.; Ur, Ehud

doi:10.1016/s0828-282x(09)70715-9

Cited by 653 publications

(508 citation statements)

References 81 publications

Supporting

Mentioning

479

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, this analysis of the multinational L-TAP 2 survey has shown that many patients who reached their LDL-C goal had persistently elevated non-HDL-C levels Hopefully, more recent recommendations [6,7] will lead to improvements in both LDL-C and non-HDL-C control worldwide.…”

Section: Discussionmentioning

confidence: 90%

“…This recommendation mainly applies to patients with plasma triglycerides (TG) of >200 mg/dL, and also pertains to patients with known coronary heart disease (CHD) [5]. The importance of non-HDL-C was recently recognized in both Canadian [6] and European Atherosclerosis [7] guidelines. However, little is known about international patterns of non-HDL-C as well as achievement of non-HDL-C goals.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

et al. 2012

View full text Add to dashboard Cite

a b s t r a c tObjective: This study evaluated the success in attaining non-HDL-cholesterol (non-HDL-C) goals in the multinational L-TAP 2 study. Methods: 9955 patients !20 years of age with dyslipidemia on stable lipid-lowering therapy were enrolled from nine countries. Results: Success rates for non-HDL-C goals were 86% in low, 70% in moderate, and 52% in high-risk patients (63% overall). In patients with triglycerides of >200 mg/dL success rates for non-HDL-C goals were 35% vs. 69% in those with 200 mg/dL (p < 0.0001). Among patients attaining their LDL-C goal, 18% did not attain their non-HDL-C goal. In those with coronary disease and at least two risk factors, only 34% and 30% attained respectively their non-HDL-C and LDL-C goals. Rates of failure in attaining both LDL-C and non-HDL-C goals were highest in Latin America. Conclusions: Non-HDL-C goal attainment lagged behind LDL-C goal attainment; this gap was greatest in higher-risk patients.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In Chinese Han people, the severity of coronary lesions (according to the Gensini score of inpatients) was increased with the elevation of the TC/HDL-C ratio, but not the TG/HDL-C ratio [15]. As the TC/HDL-C ratio was considered a more sensitive and specific index of cardiovascular risk than TC, the Canadian working group have chosen this lipid ratio as a secondary goal of therapy [16]. However, American ATP III guidelines and the 2013 ACC/AHA blood cholesterol guidelines did not define the TC/HDL-C ratio as the primary target of therapy; nor is this ratio recommended as a secondary target of therapy [2,3].…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people

Zhu

et al. 2015

Kardiol Pol

116

View full text Add to dashboard Cite

A b s t r a c tBackground and aim: Dyslipidaemia is the main risk factor for coronary heart disease (CHD). Plasma lipid levels are conventionally used to predict coronary risk globally, but further studies are required to investigate whether the lipoprotein ratios are superior to conventional lipid parameters as predictors for CHD. Methods:A hospital-based case-control study consisting of 738 CHD patients and 157 control subjects was conducted in a Chinese Han population. Demographic characteristics and plasma lipid or apolipoprotein data were collected. Univariate and multivariate logistic regression analyses were carried out to examine the relationship between the lipoprotein ratios and CHD risk. Results:The CHD group had significantly higher age, non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein (a) [Lp(a)], triglyceride (TG)/HDL-C, total cholesterol (TC)/HDL-C, low-density lipoprotein cholesterol (LDL-C)/HDL-C, non-HDL-C/HDL-C, very low-density lipoprotein cholesterol (VLDL-C)/HDL-C, and apolipoprotein B100/apolipoprotein AI (apoB100/apoAI) than the control group (p < 0.05 for all). Moreover, the prevalence of male sex, smoking, and hypertension in the CHD group was significantly higher than in the control group. The results from univariate logistic regression analysis showed that the ratios of TC/HDL-C (OR 1.135, 95% CI 1.019-1.265), LDL-C/HDL-C (OR 1.216, 95% CI 1.033-1.431), non-HDL-C/HDL-C (OR 1.135, 95% CI 1.019-1.265), and apoB100/apoAI (OR 1.966, 95% CI 1.013-3.817) significantly increased the risk for CHD. By multivariate logistic regression analysis, the results were not materially altered and each of the four ratios was independently associated with CHD after adjustment for non-lipid coronary risk factors. ApoB100/apoAI showed the strongest association with CHD in both the univariate and multivariate logistic regression analyses. Conclusions:Our data indicate that the lipoprotein ratios are superior to conventional lipid parameters as predictors for CHD. Of the ratios, apoB100/apoAI is the best to predict CHD risk.

show abstract

“…More recent studies, supported by updated Canadian guideline recommendations (13), have demonstrated that even a more aggressive lowering of LDL may be warranted. Thus, the need to titrate current statin therapy to higher doses, potentially use a combination of lipid-modifying treatments (as seen in the optimal management of hypertension) once the statin dose has been truly maximized, and optimize adherence is paramount to further bridge the gap between evidence-based medicine and current Canadian practice.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)

Goodman

Langer

Bastien

et al. 2010

Canadian Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

Cited by 653 publications

References 81 publications

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people

Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)

Contact Info

Product

Resources

About